Thomas S, Babu R J, Agarwal K, Puri V, Jain M, Andley M, Tudu S K
Department of Surgery, Lady Hardinge Medical College, Shaheed Bhagat Singh Marg, New Delhi, India.
Indian J Cancer. 2013 Jan-Mar;50(1):46-51. doi: 10.4103/0019-509X.112299.
CD10 is a zinc-dependent peptidase (metalloproteinase). Stromal CD10 expression in breast cancer correlates with poor prognosis, oestrogen receptor negativity and higher grade. CD10 may be a potential target of new cancer therapies as it is involved in cleavage of doxorubicin.
To evaluate the effect of neo-adjuvant anthracycline-based chemotherapy on status of stromal CD10 antigens in breast cancer.
Patients with invasive breast cancer scheduled for anthracycline-based neo-adjuvant chemotherapy were included in the study. Tumor stromal CD10 expression was estimated before and after 3 cycles of chemotherapy, and change in its status was correlated with clinical response to chemotherapy.
16 out of the 29 patients had strong CD10 expression; in these 16 patients, 14 (87.5%) were hormone receptor negative, and 14 (87.5%) had HER-2/neu overexpression. Stromal CD10 expression remained same in 13 out of 29 cases (44.83%) after chemotherapy. There was a change in CD10 expression in the remaining 16 cases (55.17%); in 13 cases (44.83%) it decreased from its pre-chemotherapy status, while its expression increased in 3 cases (10.34%). In cases of complete and partial clinical response, there was no increase in CD10 expression. Where CD10 expression had increased after chemotherapy, there was either a minor response or no response to chemotherapy. In 13 cases where CD10 expression had decreased, 12 cases had a clinical response to chemotherapy.
Strong CD10 expression correlates with hormone receptor negativity and HER-2/neu overexpression. Stromal CD10 expression in breast cancer is not static and changes with neo-adjuvant anthracycline-based chemotherapy. A stable or decrease in CD10 expression correlates with complete or partial clinical response, while an increase in CD10 expression appears to correlate with poor clinical response. A larger series is required to determine the clinical significance of these changes. As stromal CD10 expression and its change with chemotherapy may have a prognostic significance, they should be documented in breast cancer patients before and after chemotherapy.
CD10是一种锌依赖性肽酶（金属蛋白酶）。乳腺癌中基质CD10的表达与预后不良、雌激素受体阴性及更高分级相关。由于CD10参与阿霉素的裂解，它可能是新型癌症治疗的潜在靶点。
评估基于蒽环类药物的新辅助化疗对乳腺癌基质CD10抗原状态的影响。
计划接受基于蒽环类药物的新辅助化疗的浸润性乳腺癌患者纳入本研究。在化疗3个周期前后评估肿瘤基质CD10的表达，并将其状态变化与化疗的临床反应相关联。
29例患者中有16例CD10表达强烈；在这16例患者中，14例（87.5%）激素受体阴性，14例（87.5%）HER-2/neu过表达。化疗后29例中有13例（44.83%）基质CD10表达保持不变。其余16例（55.17%）CD10表达有变化；13例（44.83%）从化疗前状态下降，而3例（10.34%）表达增加。在完全和部分临床缓解的病例中，CD10表达没有增加。化疗后CD10表达增加的病例中，要么是轻微反应，要么对化疗无反应。在CD10表达下降的13例中，12例对化疗有临床反应。
强烈的CD10表达与激素受体阴性及HER-2/neu过表达相关。乳腺癌中的基质CD10表达不是静态的，会随着基于蒽环类药物的新辅助化疗而变化。CD10表达稳定或下降与完全或部分临床反应相关，而CD10表达增加似乎与临床反应不良相关。需要更大规模的系列研究来确定这些变化的临床意义。由于基质CD10表达及其化疗后的变化可能具有预后意义，应记录乳腺癌患者化疗前后的情况。
